See the DrugPatentWatch profile for Adbry
When does the Adbry (tralokinumab) patent expire?
Adbry’s patent expiry depends on which specific patent (or patent family) covers each aspect of the drug—such as the active ingredient, specific formulations, manufacturing methods, or later improvements. Patent expiration also can differ from regulatory exclusivity, which can extend market protection even after certain patents expire.
Because you asked only for “Adbry patent expiration,” the key missing input is the jurisdiction (for example, U.S., EU/UK, Canada, Japan) and whether you mean the first relevant expiration date or the last (latest) date across all listed patents.
How do patents and exclusivity differ for Adbry market protection?
Even after patents expire, a biologic can still face limits on competition because regulators may apply separate exclusivity periods (for example, for first approvals and related review protections). This can delay biosimilar or similar-product entry beyond the date of any single patent.
So, “patent expiration” alone may not match the real-world date when competitors can launch.
What’s the practical date to watch for biosimilar entry?
For biologics like Adbry, the practical launch window is usually driven by:
- the latest expiration date among relevant patents listed for the product, and
- any additional regulatory exclusivity that blocks approval or limits marketing.
In many markets, there isn’t one universal “Adbry expiration date.” The answer is typically the latest controlling protection date in that country plus the time needed for regulatory approval and launch logistics.
What jurisdiction should you check (and why the date changes)?
Patent terms vary by country, as do:
- how patent term adjustments/extensions apply,
- what counts as “relevant” patents for the regulator’s listed coverage,
- and whether patent litigation stays or accelerates availability of generic/biosimilar products.
If you tell me the country (e.g., U.S. vs EU/UK) I can narrow the answer to the correct legal timeline.
Which patents usually control a biologic like Adbry?
For biologics, the most consequential patents often include:
- composition and method-of-use claims related to the antibody,
- formulation or delivery-related claims (where applicable),
- and any later-life-cycle patents that were granted after the original approval (if they cover additional protected features).
The “expiration” date that matters can shift to a newer patent family if it expires later.
Can a competitor enter before all Adbry patents expire?
Usually, a biosimilar/similar product cannot be marketed in a way that infringes still-active patents. In some systems, disputes are handled through patent listing/notice procedures and court challenges. Even if regulatory approval is obtained, marketing can be blocked until protection ends or litigation resolves.
What I need from you to give an exact expiration date
Reply with:
1) Which country/region you mean (U.S., EU, UK, Canada, etc.), and
2) Whether you want the earliest patent expiry, or the last controlling date for competition.
Sources
No sources were provided with your question, so I can’t cite the exact Adbry patent expiration date yet.